Anaplastic large cell lymphoma T- and null-cell types

3 trials MedDRA PT
3 Registered trials
0 Recruiting
2 Unique sponsors
1 Unique IMPs
2 Commercial trials
Drug classes (ATC)
— ATC code not specified 3
Mechanism of action (INN-stem analysis)
Unknown / small molecule 1 substance
Phase I/II: 1 Phase I: 2

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase I/II

1 trial
  • Fondazione Italiana Linfomi Ets Academic
    ROMIDEPSIN
    2024-511639-83-00 1 country 2014 n=125 Orphan
    Ended

Phase I

2 trials
  • Seagen Inc. Commercial
    IMP not specified
    2022-502390-41-00 4 countries 2024 n=35
    Ended
  • Seagen Inc. Commercial
    IMP not specified
    2023-505813-26-00 5 countries 2024 n=48
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Seagen Inc. Commercial 2 Phase I 0
Fondazione Italiana Linfomi Ets Academic 1 Phase I/II 0
New trials by year
2024
2
← All indication landscapes